



Kelly E. Farnan  
Director  
302-651-7705  
Farnan@rlf.com

May 4, 2016

**BY CM/ECF AND HAND DELIVERY**

The Honorable Richard G. Andrews  
United States District Court  
District of Delaware  
844 N. King Street  
Wilmington, DE 19801

**Re: *Hospira, Inc. v. Amneal Pharmaceuticals LLC*, C.A. No. 15-697-RGA**

Dear Judge Andrews:

I write on behalf of Defendant Amneal Pharmaceuticals LLC (“Amneal”) in accordance with District of Delaware Local Rule 7.1.2(b) to provide the Court with supplemental authority relevant to issues raised in the Joint Claim Construction Brief (D.I. 44). Specifically, attached as Exhibit A is U.S. Patent No. 9,320,712 (the “’712 patent”) which issued to Plaintiff Hospira, Inc. on April 26, 2016. The ’712 patent issued on the same day that Amneal served its sur-reply brief and Amneal was not aware of it sufficiently in advance of the deadline to address it in the briefing that has been submitted to the Court. Amneal believes that the ’712 patent, which is part of the intrinsic record of the other patents-in-suit, contains disclosure relevant to the construction of at least the term “dexmedetomidine” and Amneal will briefly address the ’712 patent at the claim construction hearing scheduled for May 12, 2016.

If Your Honor has any questions concerning the foregoing, counsel remains available at the Court’s convenience.

Respectfully,

*/s/ Kelly E. Farnan*

Kelly E. Farnan (#4395)

cc: Counsel of Record (by CM/ECF)

